Pharmacokinetic and Pharmacodynamic Evaluation of Liposomal Amikacin for Inhalation in Cystic Fibrosis Patients with Chronic Pseudomonal Infection

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  2009-05-18

• Fields of study

  Medicine

• Identifiers
  DOI 10.1128/AAC.00872-08PMID 19451281PMCID PMC2737891
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Nonparametric Statistical Inference

  2020cited by this paper
• Berichten

  2005cited by this paper
• Bringing new treatments to the bedside in cystic fibrosis

  2004cited by this paper
• Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis.

  2002cited by this paper
• Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis.

  2002cited by this paper
• Serum pharmacokinetics and sputum penetration of amikacin 30 mg/kg once daily and of ceftazidime 200 mg/kg/day as a continuous infusion in cystic fibrosis patients.

  2001cited by this paper
• Inhalation of antibiotics in cystic fibrosis.

  1995cited by this paper
• A Bayesian extension of the minimum AIC procedure of autoregressive model fitting

  1979cited by this paper

• Breaking the Biofilm Barrier: Nano-based Antibacterial Delivery

  2026cites this paper
• Liposomal antimicrobials in the fight against bacterial and fungal pathogens: Clinical successes and development challenges

  2025cites this paper
• Liposomes for Inhalation

  2024cites this paper
• Inhalable spray-dried porous microparticles containing dehydroandrographolide succinate phospholipid complex capable of improving and prolonging pulmonary anti-inflammatory efficacy in mice

  2024cites this paper
• A New Insight into Phage Combination Therapeutic Approaches Against Drug-Resistant Mixed Bacterial Infections

  2024cites this paper
• Antibiotic loaded inhalable liposomal nanoparticles against lower respiratory tract infections: Challenges, recent advances, and future perspectives

  2024cites this paper
• Colistin- and Amikacin-loaded lipid-based drug delivery systems for resistant gram-negative lung and wound bacterial infections.

  2023cites this paper
• Micro and nano-carriers-based pulmonary drug delivery system: Their current updates, challenges, and limitations – A review

  2023cites this paper
• Harnessing inhaled nanoparticles to overcome the pulmonary barrier for respiratory disease therapy.

  2023cites this paper
• Inhaled anti-pseudomonal antibiotics for long-term therapy in cystic fibrosis.

  2022cites this paper
• Liposomal Delivery of Newly Identified Prophage Lysins in a Pseudomonas aeruginosa Model

  2022cites this paper
• Medicinal Chemistry of Inhibitors Targeting Resistant Bacteria.

  2022cites this paper
• Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis.

  2022cites this paper
• Liposome-Encapsulated Tobramycin and IDR-1018 Peptide Mediated Biofilm Disruption and Enhanced Antimicrobial Activity against Pseudomonas aeruginosa

  2022cites this paper
• Inhalable liposomes for treating lung diseases: clinical development and challenges

  2021cites this paper
• Application of nanotechnology in drug delivery systems for respiratory diseases

  2021cites this paper
• Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Drug Treatment of Non-Tuberculous Mycobacteria in Cystic Fibrosis

  2021cites this paper
• Pharmacotherapy for nontuberculous mycobacterial pulmonary disease.

  2021cites this paper
• Pharmacokinetic and Pharmacodynamic Optimization of Antibiotic Therapy in Cystic Fibrosis Patients: Current Evidences, Gaps in Knowledge and Future Directions

  2021cites this paper
• Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment-Refractory Nontuberculous Mycobacterial Lung Disease

  2021cites this paper
• Delivery of Drug Payloads to Organs and Organ-Systems

  2021cites this paper
• Inhaled Liposomal Antimicrobial Delivery in Lung Infections

  2020cites this paper
• Methodological features of clinical pharmacokinetic-pharmacodynamic studies of antibacterials and antifungals: a systematic review.

  2020cites this paper
• Liposomes in the treatment of chronic respiratory conditions

  2020cites this paper
• Novel Therapeutic Strategies Applied to Pseudomonas aeruginosa Infections in Cystic Fibrosis

  2019cites this paper
• Interactions with the macrophages: An emerging targeted approach using novel drug delivery systems in respiratory diseases.

  2019cites this paper
• Current Practices and Potential Nanotechnology Perspectives for Pain Related to Cystic Fibrosis

  2019cites this paper
• A critical review of definitions used to describe Pseudomonas aeruginosa microbiological status in patients with cystic fibrosis for application in clinical trials.

  2019cites this paper
• Nanomedicine Approaches for the Pulmonary Treatment of Cystic Fibrosis

  2019cites this paper
• Strategies to prevent the occurrence of resistance against antibiotics by using advanced materials

  2018cites this paper
• Attenuation of Pseudomonas aeruginosa biofilm by hordenine: a combinatorial study with aminoglycoside antibiotics

  2018cites this paper
• In vitro evaluation of aerosol delivery of aztreonam lysine (AZLI): an adult mechanical ventilation model

  2017cites this paper
• Lipid-Based Nanopharmaceuticals in Antimicrobial Therapy

  2017cites this paper
• Nanostructures for Antimicrobial Therapy—The Modern Trends in the Treatment of Bacterial Infections

  2017cites this paper
• Waters, Valerie and Smyth, Alan R. (2015) Cystic fibrosis microbiology: advances in antimicrobial therapy. Journal of Cystic Fibrosis, 14 (5). pp. 551-560. 1873-5010

  2017cites this paper
• Macromolecular Conjugate and Biological Carrier Approaches for the Targeted Delivery of Antibiotics

  2017cites this paper
• Nanostructured coatings for controlling bacterial biofilms and antibiotic resistance

  2017cites this paper
• Nanosized devices as antibiotics and antifungals delivery: past, news, and outlook

  2017cites this paper
• Pulmonary delivery of tobramycin-loaded nanostructured lipid carriers for Pseudomonas aeruginosa infections associated with cystic fibrosis.

  2016cites this paper
• Pharmacokinetic Considerations of Inhaled Pharmaceuticals for Systemic Delivery.

  2016cites this paper
• Formulation and Evaluation of Rifampicin Liposomes for Buccal Drug Delivery.

  2016cites this paper
• Challenges and Successes Using Nanomedicines for Aerosol Delivery to the Airways.

  2016cites this paper
• Formulation and efficacy of liposome-encapsulated azithromycin for pulmonary infection due to Pseudomonias Aeruginosa

  2016cites this paper
• Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease

  2016cites this paper
• Management of Pseudomonas aeruginosa infection in cystic fibrosis patients using inhaled antibiotics with a focus on nebulized liposomal amikacin.

  2015cites this paper
• Nanoscale Formulations and Diagnostics With Their Recent Trends: A Major Focus of Future Nanotechnology.

  2015cites this paper
• Cystic fibrosis microbiology: Advances in antimicrobial therapy.

  2015cites this paper
• T100: nebulized-concentrated tobramycin formulation for treatment of Pseudomonas aeruginosa infection in cystic fibrosis patients

  2015cites this paper
• Modern Therapeutic Approaches Against Pseudomonas aeruginosa Infections.

  2015cites this paper
• Clinical Pharmacokinetics of Inhaled Antimicrobials

  2015cites this paper
• Nanovecteurs pour cibler pseudomonas aeruginosa dans la fibrose kystique

  2015cites this paper
• Pseudomonas aeruginosa quorum sensing molecules correlate with clinical status in cystic fibrosis

  2015cites this paper
• Pharmacokinetics and Pharmacodynamics of Aerosolized Antibacterial Agents in Chronically Infected Cystic Fibrosis Patients

  2014influential citation
• Medical nanoparticles for next generation drug delivery to the lungs

  2014cites this paper
• Improving the efficacy of inhaled drugs in cystic fibrosis: challenges and emerging drug delivery strategies.

  2014cites this paper
• Nano-antibiotics in chronic lung infection therapy against Pseudomonas aeruginosa.

  2014cites this paper
• New perspectives in the management of Pseudomonas aeruginosa infections.

  2014cites this paper
• Lipid-based carriers for pulmonary products: preclinical development and case studies in humans.

  2014cites this paper
• Nanomedicines in the future of pediatric therapy.

  2014cites this paper
• Liposomal antibiotic formulations for targeting the lungs in the treatment of Pseudomonas aeruginosa.

  2014cites this paper
• Inhaled Antibiotics in the Treatment of Nosocomial Pneumonia

  2014cites this paper
• Nebulized liposomal amikacin for the treatment of Pseudomonas aeruginosa infection in cystic fibrosis patients

  2014cites this paper
• Evaluation of the Pharmacokinetics and Pharmacodynamics of Liposomal Amikacin for Inhalation in Cystic Fibrosis Patients with Chronic Pseudomonal Infections Using Data from Two Phase 2 Clinical Studies

  2014influential citation
• Nanocarriers for antibiotics: a promising solution to treat intracellular bacterial infections.

  2014cites this paper
• New treatments in development for Pseudomonas aeruginosa infections in the lungs of individuals with cystic fibrosis

  2014cites this paper
• Inhaled liposomal amikacin

  2014cites this paper
• Aerosolised levofloxacin in cystic fibrosis

  2013cites this paper
• Development of liposomal formulations: From concept to clinical investigations

  2013cites this paper
• Liposome-Entrapped Antibiotics: Recent Progress and Clinical Applications

  2013cites this paper
• Design, characterization, and aerosolization of organic solution advanced spray-dried moxifloxacin and ofloxacin dipalmitoylphosphatidylcholine (DPPC) microparticulate/nanoparticulate powders for pulmonary inhalation aerosol delivery

  2013cites this paper
• Inhaled antibiotics to treat lung infection.

  2013cites this paper
• Novel amikacin inhaled formulation for the treatment of lower respiratory tract infections.

  2013cites this paper
• Inhaled aztreonam lysine: an evidence-based review

  2013cites this paper
• Cystic fibrosis therapeutics: the road ahead.

  2013cites this paper
• Drug Delivery: Pulmonary Delivery

  2013cites this paper
• From pipeline to patient: new developments in cystic fibrosis therapeutics

  2013cites this paper
• Liposomal formulations for inhalation.

  2013cites this paper
• 99mTc-labeled therapeutic inhaled amikacin loaded liposomes

  2013influential citation
• Current Approaches to the Management of Infection in Cystic Fibrosis

  2013cites this paper
• New treatments for emerging cystic fibrosis pathogens other than Pseudomonas.

  2012cites this paper
• Therapeutic Liposomal Dry Powder Inhalation Aerosols for Targeted Lung Delivery

  2012cites this paper
• Pharmacokinetics and disposition of various drug loaded liposomes.

  2012cites this paper
• Challenges with current inhaled treatments for chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis

  2012cites this paper
• New developments in inhaled antibiotics for the treatment of Pseudomonas aeruginosa.

  2012cites this paper
• Treatment of lung infection in patients with cystic fibrosis: current and future strategies.

  2012cites this paper
• Inhaled Aztreonam Lysine for Cystic Fibrosis Pulmonary Disease–Related Outcomes

  2012influential citation
• 10 Antimicrobial Biomimetics

  2012cites this paper
• Use of Inhaled Tobramycin for the Treatment of Severe Nosocomia Pneumonia

  2012cites this paper
• Novel Concept in Pulmonary Delivery

  2012cites this paper
• Severe nosocomial pneumonia – emphasis on nebulized tobramycin

  2012cites this paper
• CHEST Ahead of the Curve Cystic Fibrosis Therapeutics The Road Ahead

  2012cites this paper
• El futuro de la antibioterapia inhalada. Nuevos productos

  2011cites this paper
• Fate of nanomedicines in the lungs

  2011cites this paper
• Pseudomonas aeruginosa Infection in Cystic Fibrosis: A Paradigm of Chronic Infection

  2011cites this paper
• [The future of inhaled antibiotic therapy. New products].

  2011cites this paper
• Pulmonary & Respiratory Medicine

  2011cites this paper
• Adults with Cystic Fibrosis

  2011cites this paper
• Transmucosal and Ocular Drug Delivery

  2011cites this paper
• Pulmonary Delivery: Innovative Approaches and Perspectives

  2011cites this paper
• Antibiotic treatment of CF lung disease: from bench to bedside.

  2011cites this paper